Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2092]

ESMO 2018: Major response to immunotherapy in early stage mismatch repair deficient colon cancer

ESMO 2018: Major response to immunotherapy in early stage mismatch repair deficient colon cancer

ESMO 2018: Barriers to early clinical trial access for adolescents and young adults still exist, study shows

ESMO 2018: Barriers to early clinical trial access for adolescents and young adults still exist, study shows

ESMO 2018: Drugs for treating breast cancer in women are effective and well tolerated in men

ESMO 2018: Drugs for treating breast cancer in women are effective and well tolerated in men

ESMO 2018: Olaparib maintenance extends PFS by estimated 3 years in advanced ovarian cancer

ESMO 2018: Olaparib maintenance extends PFS by estimated 3 years in advanced ovarian cancer

ESMO 2018: Zoledronic acid improves disease-free survival in premenopausal HR early breast cancer

ESMO 2018: Zoledronic acid improves disease-free survival in premenopausal HR early breast cancer

ESMO 2018: Targeting specific genomic mutation in breast cancer improves outcomes, first study shows

ESMO 2018: Targeting specific genomic mutation in breast cancer improves outcomes, first study shows

ESMO 2018: Some patients with metastatic triple negative breast cancer live longer with immunotherapy

ESMO 2018: Some patients with metastatic triple negative breast cancer live longer with immunotherapy

ESMO 2018: New option for women with advanced breast cancer resistant to hormone therapy

ESMO 2018: New option for women with advanced breast cancer resistant to hormone therapy

ESMO 2018: AACR CEO Margaret Foti Honored with Women for Oncology Award from ESMO

ESMO 2018: AACR CEO Margaret Foti Honored with Women for Oncology Award from ESMO

ESMO 2018: Oncologists demand more education on the use of biosimilars

ESMO 2018: Oncologists demand more education on the use of biosimilars

More from ecancer